| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -19,306 | -12,118 |
| Amortization of premium on short-term investments | - | 1,107 |
| Depreciation and amortization | 118 | 115 |
| Non-cash operating lease expense | 142 | 139 |
| Foreign currency exchange loss, net | -579 | 395 |
| Share-based compensation expense | 1,374 | 981 |
| Accrued interest on borrowings | 129 | 129 |
| Gain on extinguishment of borrowings | 5,203 | 5,203 |
| Impairment of property, plant, and equipment and rou asset | 363 | 323 |
| Loss on the sale of property, plant, and equipment | -358 | -358 |
| Prepaid expenses and other current assets | -669 | 631 |
| Other non-current assets | -87 | -85 |
| Accounts payable | -1,264 | -1,465 |
| Accrued expenses and other current liabilities | -8,167 | -6,467 |
| Operating lease liabilities | -141 | -138 |
| Net cash used in operating activities | -30,262 | -25,394 |
| Proceeds from sale of property and equipment | 288 | 283 |
| Maturities of investments | 40,076 | 47,000 |
| Purchases of investments | - | 34,621 |
| Net cash provided by investing activities | 40,364 | 12,662 |
| Net decrease in cash and cash equivalents | 10,102 | -12,732 |
| Effect of exchange rate changes on cash | 4,547 | - |
| Cash and cash equivalents at beginning of period | 35,015 | - |
| Cash and cash equivalents at end of period | 49,664 | - |
LAVA Therapeutics NV (LVTX)
LAVA Therapeutics NV (LVTX)